Here are the The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis journals presenting the latest research across various disciplines. From social sciences to technology, each article is expected to provide valuable insights to our readers.
What is the long term capital gains rate, the long term effects of dapagliflozin metformin, what are the long term effects of covid, the long term effects of dapagliflozin in chronic kidney, the long term effects of alcohol, the longest day, the longest ride, the long term effects of dapagliflozin drug, the long term effects of dapagliflozin in patients.
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
Background. Chronic kidney disease (CKD) presents a significant clinical and economic burden to healthcare systems worldwide, which increases considerably with progression towards kidney failure. The Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial demonstrated that patients with or without type 2 diabetes who were treated with dapagliflozin experienced slower progression of CKD versus those receiving placebo. Understanding the effect of long-term treatment with dapagliflozin on the timing of kidney failure beyond trial follow-up can assist informed decision-making by healthcare providers and patients. The study objective was therefore to extrapolate the outcome-based clinical benefits of treatment with dapagliflozin in patients with CKD via a time-to-event analysis using trial data. Methods. Patient-level data from the DAPA-CKD trial were used to parameterize a closed cohort-level partitioned survival model that predicted time-to-ev ent for key trial endpoints (kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure). Data were pooled with a subpopulation of the Dapagliflozin Effect on Cardiovascular Events – Thrombolysis in Myocardial Infarction 58 (DECLARE-TIMI 58) trial to create a combined CKD population spanning a range of CKD stages; a parallel survival analysis was conducted in this population. Results. In the DAPA-CKD and pooled CKD populations, treatment with dapagliflozin delayed time to first event for kidney failure, all-cause mortality, sustained decline in kidney function and hospitalization for heart failure. Attenuation of CKD progression was predicted to slow the time to kidney failure by 6.6 years [dapagliflozin: 25.2, 95% confidence interval (CI) 19.0–31.5; standard therapy: 18.5, 95% CI 14.7–23.4] in the DAPA-CKD population. A similar result was observed in the pooled CKD population with an estimated delay of 6.3 years (dapagliflo zin: 36.0, 95% CI 31.9–38.3; standard therapy: 29.6, 95% CI 25.5–34.7). Conclusion. Treatment with dapagliflozin over a lifetime time horizon may considerably delay the mean time to adverse clinical outcomes for patients who would go on to experience them, including those at modest risk of progression. © The Author(s) 2024.
Authors : McEwan P.; Gabb P.D.; Davis J.A.; Sanchez J.J.G.; Sjöström C.D.; Barone S.; Kashioulis P.; Ouwens M.; Cassimaty S.; Correa-Rotter R.; Rossing P.; Wheeler D.C.; Heerspink H.J.L.
Source : Oxford University Press
Article Information
| Year | 2024 |
| Type | Article |
| DOI | 10.1093/ndt/gfae106 |
| ISSN | 09310509 |
| Volume | 39 |
You can download the article here
If You have any problem, contact us here